If sufficient data are not available such that adequate interpretation of the result is not warranted, some summaries may not be performed and only listings will be presented. E fficacy analyses will be perf ormed using the RECIST v1.1 (all indications except prostate) or PCWG3 criteria (prostate). Details on censoring scheme on time- to-event endpoints such as DOR, PFS, and OS will be described in the SAP. A description of the participant population will be included in the statistical output reported, including subgroup of age, gender, and race. 10.3.1 Efficacy Analyses Endpoint Statistical Analysis Methods ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR for a participant will be assessed per RECIST v1.1 or PCWG 3 (for prostate cancer) by investigatorEstimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method mDOR DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1 / PCWG3 or death, whichever occurs first.mDOR using the Kaplan-Meier method and corresponding two 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation), if appropriate PFSR at 24 weeks PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 95% CI will be derived based on Greenwood formula Abbreviations: BOR = best overall response; CI = confid ence interval; CR = complete response; DOR = duration of response; mDOR = median duration of response; ORR = objective response rate; PCWG = Prostate Cancer Working Group; PFS = progression free survival; PFSR = progr ession free survival rate; PR = partial response; RECIST = Response Evaluation Criteria In Solid Tumors. Revised Protocol No.: 04 Date: 31-May-2019 149 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 10.3.2 Safety Analyses All safety analyses for will be performed on the treated population.